A CD3+ count-based thymoglobulin induction regimen permits delayed introduction of calcineurin inhibitors in kidney transplantation

Clinical Transplantation

Volumn 26, Issue 6, 2012, Pages 900-909

  Wang, Connie J ^a   Tuffaha, Ahmad ^a   Zhang, Da ^b   Diederich, Dennis A ^a   Wetmore, James B ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Calcineurin inhibitors; CD3+ cells; Delayed graft function; Immunosuppression; Kidney transplantation; Thymoglobulin

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CEFAZOLIN; CLOTRIMAZOLE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BK VIRUS INFECTION; CD3+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DRUG DOSE INCREASE; DRUG FEVER; FEMALE; GRAFT SURVIVAL; HUMAN; INFECTION PREVENTION; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYCOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTILYMPHOCYTE SERUM; CALCINEURIN; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84870688558     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2012.01656.x     Document Type: Article

References (50)

1. Koning OH, Ploeg RJ, van Bockel JH et al. Risk factors for delayed graft function in cadaveric kidney transplantation: a prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors. European Multicenter Study Group. Transplantation 1997: 63: 1620.
2. Yarlagadda SG, Coca SG, Formica RN Jr, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant 2009: 24: 1039.
3. Mehrabi A, Mood Zh A, Sadeghi M et al. Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation. Nephrol Dial Transplant 2007: 22(Suppl 8): viii54.
4. Daly PJ, Power RE, Healy DA, Hickey DP, Fitzpatrick JM, Watson RW. Delayed graft function: a dilemma in renal transplantation. BJU Int 2005: 96: 498.
5. Curtis JJ. Renovascular elements of the cyclosporine injury. Transplant Proc 1996: 28: 2094.
6. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol 1993: 17: 60.
7. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009: 4: 481.
8. Gaber AO, Knight RJ, Patel S, Gaber LW. A review of the evidence for use of thymoglobulin induction in renal transplantation. Transplant Proc 2010: 42: 1395.
9. Ponticelli C, Scolari MP. Calcineurin inhibitors in renal transplantation still needed but in reduced doses: a review. Transplant Proc 2010: 42: 2205.
10. Vincenti F, Grinyo J, Ramos E et al. Can antibody prophylaxis allow sparing of other immunosuppressives? Transplant Proc 1999: 31: 1246.
11. Vincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001: 71: 1282.
12. Kamar N, Garrigue V, Karras A et al. Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study. Am J Transplant 2006: 6: 1042.
13. Sharif A. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 2011: 22: 2107.
14. Hong JC, Kahan BD. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function. Transplantation 2001: 71: 1320.
15. Norman DJ, Kahana L, Stuart FP Jr et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993: 55: 44.
16. Sageshima J, Ciancio G, Chen L, Burke GW 3rd. Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation. Biologics 2009: 3: 319.
17. Wilson CH, Brook NR, Gok MA, Asher JF, Nicholson ML, Talbot D. Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants. Br J Surg 2005: 92: 681.
18. Knight RJ, Kerman RH, Schoenberg L et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 2004: 78: 904.
19. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009: 48: 772.
20. Halloran PF, Hunsicker LG. Delayed graft function: state of the art, November 10-11, 2000. Summit meeting, Scottsdale, Arizona, USA. Am J Transplant 2001: 1: 115.
21. Inman SR, Davis NA, Mazzone ME, Olson KM, Lukaszek VA, Yoder KN. Simvastatin and L-arginine preserve renal function after ischemia/reperfusion injury. Am J Med Sci 2005: 329: 13.
22. Patel SJ, Duhart BT Jr, Krauss AG et al. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction. Transplantation 2008: 86: 313.
23. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006: 355: 1967.
24. Jochmans I, Pirenne J. Graft quality assessment in kidney transplantation: not an exact science yet! Curr Opin Organ Transplant 2011: 16: 174.
25. Moore J, Tan K, Cockwell P et al. Predicting early renal allograft function using clinical variables. Nephrol Dial Transplant 2007: 22: 2669.
26. Dunn TB, Noreen H, Gillingham K et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011: 11: 2132.
27. Ciancio G, Burke GW, Suzart K et al. The use of daclizumab, tacrolimus and mycophenolate mofetil in African-American and Hispanic first renal transplant recipients. Am J Transplant 2003: 3: 1010.
28. Favi E, Gargiulo A, Spagnoletti G et al. Induction with basiliximab plus thymoglobulin is effective and safe in old-for-old renal transplantation: six-month results of a prospective clinical study. Transplant Proc 2010: 42: 1114.
29. Ruggenenti P, Codreanu I, Cravedi P, Perna A, Gotti E, Remuzzi G. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. Clin J Am Soc Nephrol 2006: 1: 546.
30. Sageshima J, Ciancio G, Gaynor JJ et al. Addition of anti-CD25 to thymoglobulin for induction therapy: delayed return of peripheral blood CD25-positive population. Clin Transplant 2011: 25: E132.
31. Abouna GM, Al-Abdullah IH, Kelly-Sullivan D et al. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring. Transplantation 1995: 59: 1564.
32. Clark KR, Forsythe JL, Shenton BK, Lennard TW, Proud G, Taylor RM. Administration of ATG according to the absolute T lymphocyte count during therapy for steroid-resistant rejection. Transpl Int 1993: 6: 18.
33. Cosimi AB, Wortis HH, Delmonico FL, Russell PS. Randomized clinical trial of antithymocyte globulin in cadaver renal allograft recipients: importance of T cell monitoring. Surgery 1976: 80: 155.
34. Gorrie M, Thomson G, Lewis DM et al. Dose titration during anti-thymocyte globulin therapy: monitoring by CD3 count or total lymphocyte count? Clin Lab Haematol 1997: 19: 53.
35. Thomas FT, Griesedieck C, Thomas J et al. Differential effects of horse ATG and rabbit ATG on T cell and T cell subset levels measured by monoclonal antibodies. Transplant Proc 1984: 16: 1561.
36. Uber WE, Uber LA, VanBakel AB et al. CD3 monitoring and thymoglobulin therapy in cardiac transplantation: clinical outcomes and pharmacoeconomic implications. Transplant Proc 2004: 36: 3245.
37. Djamali A, Turc-Baron C, Portales P et al. Low dose antithymocyte globulins in renal transplantation: daily versus intermittent administration based on T-cell monitoring. Transplantation 2000: 69: 799.
38. Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002: 73: 1514.
39. Brennan DC, Flavin K, Lowell JA et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999: 67: 1011.
40. Deeks ED, Keating GM. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs 2009: 69: 1483.
41. Gaber AO, Monaco AP, Russell JA, Lebranchu Y, Mohty M. Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs 2010: 70: 691.
42. Regan JF, Lyonnais C, Campbell K, Smith LV, Buelow R. Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrations. Transpl Immunol 2001: 9: 29.
43. Guttmann RD, Flemming C. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin. Clin Transplant 1997: 11: 185.
44. Lange H, Muller TF, Ebel H et al. Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Transpl Int 1999: 12: 2.
45. Mourad G, Garrigue V, Squifflet JP et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001: 72: 1050.
46. Organ Procurement and Transplantation Network (OPTN)/Scientific Registry of Transplant Recipients (SRTR). 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, 2011: 23.
47. OPTN/SRTR. Annual Report, 2009. http://www.ustransplant.org/annual_reports/current/iKI_Recipients_survival_rate.htm?o=2&g=2&c=18.
48. Wiland AM, Fink JC, Philosophe B et al. Peripheral administration of thymoglobulin for induction therapy in pancreas transplantation. Transplant Proc 2001: 33: 1910.
49. Marvin MR, Droogan C, Sawinski D, Cohen DJ, Hardy MA. Administration of rabbit antithymocyte globulin (thymoglobulin) in ambulatory renal-transplant patients. Transplantation 2003: 75: 488.
50. Padiyar A, Augustine JJ, Hricik DE. Induction antibody therapy in kidney transplantation. Am J Kidney Dis 2009: 54: 935.